VGXI Announces Participation in the 2019 ASGCT Annual Meeting

THE WOODLANDS, Texas, April 4, 2019 /PRNewswire-PRWeb/ -- VGXI, Inc., an industry leading plasmid DNA contract manufacturing organization today announced that Mr. Stephen Rodriguez, Sr. Manager, Process Development, will be presenting during the Tools and Technologies Forum of the ASGCT Annual Meeting in Washington DC on Tuesday, April 30, 2019 at 5:00 PM ET. The presentation is titled "Plasmid DNA Manufacturing for Gene Therapy Vectors" and will focus on VGXI's experience and solutions for the production of viral vector plasmids used as a critical raw material in GMP manufacturing of AAV, lentivirus, and other gene and cell therapy products. These DNA plasmid sets have unique considerations and requirements both upstream during fermentation and downstream through the purification process. The 2019 Tools and Technologies Forum will be Mr. Rodriguez's second consecutive year presenting at ASGCT.

With over 15 years of experience supplying cGMP plasmid to clients worldwide, VGXI offers a full spectrum of manufacturing and support services. Representatives will be available during the conference at VGXI's exhibit booth, #411, to answer questions or discuss your unique project requirements. Requests for a one-on-one meeting during the event are also welcome. Contact VGXI today to arrange a meeting.

Visit the conference website for more information or to register for the event:

VGXI, Inc. has over 15 years of experience and is a leading provider of manufacturing and development services for DNA vaccines and gene therapies. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI's ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CMO of GeneOne Life Science, Inc. To learn more or request a quote, visit

GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) is an international DNA vaccine and product developer and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines and products to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit

Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.